ResultsIQ › Latest results › Amrutanjan Health Care Limited

Amrutanjan Health Care Limited Q2 FY26 results deck summary

NSE: AMRUTANJAN · BSE: 590006

Results deck of 10 Nov 2025, summarised by AI from the filing.

Q2 FY26 revenue from operations ₹117.70 cr (growth 7.08%) and profit after tax ₹15.94 cr (growth 18.31%), with GST impact on quarter end billing.

Key takeaways

Q2 revenue Revenue from operations ₹117.70 cr (Q2 FY25: ₹109.92 cr, growth 7.08%); profit after tax ₹15.94 cr (Q2 FY25: ₹13.96 cr, growth 18.31%).
Comfy reach Focus on increasing reach of Comfy from 0.5 million outlets to 1m over the next 3 years.
GST impact New GST law effective late September impacted quarter end billing, resulting in softness in reported top line.

Original filing on BSE

Amrutanjan Health Care Limited Q1 FY27 results

As filed: Revenue ₹103 cr (+10% year on year), EBITDA ₹6.3 cr (−31% year on year), PAT ₹4.4 cr (−26% year on year), EBITDA margin 6.1% (−350 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

Q4 FY26: Revenue ₹150 cr (+11% year on year), EBITDA ₹25.6 cr (+42% year on year), PAT ₹16.2 cr (+36% year on year), EBITDA margin 17.1% (+373 bps). Score 64 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend; profit before exceptional items growth was above it. EBITDA margin rose 373 bps year on year. Share price after the results: +0.6% in 28 days (Nifty 500: −2.8%).
Q3 FY26: Revenue ₹141 cr (+15% year on year), EBITDA ₹25.2 cr (+5% year on year), PAT ₹19.5 cr (+2% year on year), EBITDA margin 17.8% (−167 bps). Score 41 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 167 bps year on year. Share price after the results: −2.1% in 30 days (Nifty 500: −3.2%).
Q2 FY26: Revenue ₹118 cr (+7% year on year), EBITDA ₹17.0 cr (+21% year on year), PAT ₹14.0 cr (+17% year on year), EBITDA margin 14.4% (+168 bps). Score 40 of 100, In line with trend. Revenue and EBITDA growth were below the company's own trend; profit growth was in line with it. EBITDA margin rose 168 bps year on year. Revenue rose ₹8.0 cr on a year ago, against ₹11.0 cr the year before. Share price after the results: −7.1% in 30 days (Nifty 500: −0.8%).
Q1 FY26: Revenue ₹94.0 cr (+12% year on year), EBITDA ₹9.0 cr (+125% year on year), PAT ₹8.0 cr (+60% year on year), EBITDA margin 9.6% (+481 bps). Score 59 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 481 bps year on year. Other income 36% of PBT. Revenue fell 30% from last quarter. Share price after the results: +11.7% in 30 days (Nifty 500: +2.4%).
Q4 FY25: Revenue ₹135 cr (+6% year on year), EBITDA ₹18.0 cr (+13% year on year), PAT ₹15.0 cr (+7% year on year), EBITDA margin 13.3% (+73 bps). Score 36 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin rose 73 bps year on year. Profit fell 21% from last quarter. Share price after the results: −3.0% in 29 days (Nifty 500: +0.5%).
Q3 FY25: Revenue ₹123 cr (+5% year on year), EBITDA ₹24.0 cr (+9% year on year), PAT ₹19.0 cr (+12% year on year), EBITDA margin 19.5% (+71 bps). Score 33 of 100, Below trend. Revenue growth was well below the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 71 bps year on year.
Q2 FY25: Revenue ₹110 cr (+11% year on year), EBITDA ₹14.0 cr (+100% year on year), PAT ₹12.0 cr (+71% year on year), EBITDA margin 12.7% (+566 bps). Score 83 of 100, Above trend. EBITDA margin rose 566 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Amrutanjan Health Care Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.